Rebecca Gohmann Bechhold

Title
InstitutionMedical University of South Carolina
DepartmentMedicine
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Yardley DA, Peacock NW, Shastry M, Burris HA, Bechhold RG, Hendricks CB, Yoshizawa CN, Sing AP, Hainsworth JD, Yardley DA, Peacock NW, Shastry M, Burris HA, Bechhold RG, Hendricks CB, Yoshizawa CN, Sing AP, Hainsworth JD. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Res Treat. 2015 Nov; 154(2):299-308. PMID: 26507191.
      Citations:    
    2. Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT, Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. J Clin Oncol. 2015 May 10; 33(14):1609-19. PMID: 25847941.
      Citations:    
    3. Yardley DA, Zubkus JD, Eakle JF, Bechhold RG, Finney L, Daniel D, Daniel B, Hainsworth JD, Yardley DA, Zubkus JD, Eakle JF, Bechhold RG, Finney L, Daniel D, Daniel B, Hainsworth JD. Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute. Clin Breast Cancer. 2015 Aug; 15(4):251-8. PMID: 25640059.
      Citations:    
    4. Bechhold R, Bechhold R. Nobody's poster child. Oncology (Williston Park). 2014 Sep; 28(9):C3. PMID: 25741560.
      Citations:    
    5. Bechhold R, Bechhold R. Survivorship is not a passive sport. Oncology (Williston Park). 2014 Jun; 28(6):533-4. PMID: 25134332.
      Citations:    
    6. Bechhold R, Bechhold R. The F-word. Oncology (Williston Park). 2013 Sep; 27(9):922-3. PMID: 24282991.
      Citations:    
    7. Bechhold R, Bechhold R. Straightforward oncology: How honest is the EMR? Oncology (Williston Park). 2013 Aug; 27(8):769. PMID: 24133823.
      Citations:    
    Bechhold's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (54)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _